This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/drugbank/drug/DB05829/identifier/drugbank/
n4http://linked.opendata.cz/resource/drugbank/dosage/
n15http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n8http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/resource/drugbank/drug/DB05829/identifier/uniprotkb/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://linked.opendata.cz/resource/drugbank/drug/DB05829/identifier/wikipedia/
n12http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/drugbank/drug/DB05829/identifier/kegg-compound/
n14http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB05829
rdf:type
n3:Drug
n3:description
Preotact is a pharmaceutical form of parathyroid hormone (PTH). PTH is a single-chain polypeptide composed of 84 amino acids. Preotact contains recombinant human parathyroid hormone which is identical to the full-length native 84-amino acid polypeptide. It is produced as a fusion protein. Post-translational processing involves the cleavage of the OmpA leader sequence, leaving the mature protein as a single-chain 84 amino-acids polypeptide (9.4 kDa) whose sequence is identical to that of the full-length native endogenous human PTH. It has no disulfide bonds and no glycosylation sites. Preotact is used in the treatment of osteoporosis in postmenopausal women at high risk of osteoporotic fractures. Preotact is marketed in Europe by Nycomed. Preos is a registered trade mark owned by NPS Pharmaceuticals, Inc. The name Preos and the New Drug Application is pending approval by the U.S. Food and Drug Administration (FDA).
n3:dosage
n4:271B4774-363D-11E5-9242-09173F13E4C5 n4:271B4776-363D-11E5-9242-09173F13E4C5 n4:271B4777-363D-11E5-9242-09173F13E4C5 n4:271B4775-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Sosa Henriquez M, Diez Perez A: [Parathyroid hormone in the treatment of osteoporosis] An Med Interna. 2007 Feb;24(2):87-97. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17590097
n3:group
approved investigational
n3:halfLife
The mean half-life is approximately 1.5 hours.
n3:indication
For use/treatment in osteoporosis.
owl:sameAs
n8:DB05829 n15:DB05829
dcterms:title
Preotact
adms:identifier
n6:DB05829 n10:C16051 n11:P01270 n16:Preotact
n3:mechanismOfAction
The biological actions of rhPTH are mediated through binding to at least two distinct high- affinity cell-surface receptors specific for the N-terminal and C-terminal regions of the molecule, both of which are required for normal bone metabolism. The N-terminal portion of the molecule is primarily responsible for the bone building effects of parathyroid hormone. The C-terminal portion of the molecule has antiresorptive activity and is necessary for normal regulation of N-terminal fragment activity.
n3:routeOfElimination
Not excreted from the body in its intact form. Circulating carboxy-terminal fragments are filtered by the kidney, but are subsequently broken down into even smaller fragments during tubular reuptake.
n3:synonym
rPTH(1-84) hPTH(1-84) Parathormone (human recombinant) rhPTH PTH(1-84) Parathyroid hormone (r.E.coli) PTH rhPTH(1-84) Parathormone rPTH Parathyrin Parathyroid hormone hPTH
n3:volumeOfDistribution
The volume of distribution at steady-state following intravenous administration is approximately 5.4 liters. Intersubject variability is about 40%.
n3:synthesisReference
Robert L. Colescott, Geoffrey W. Tregear, "Synthesis of peptides with parathyroid hormone activity." U.S. Patent US4105602, issued May, 1977.
n3:Molecular-Formula
n12:271B4779-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n12:271B4778-363D-11E5-9242-09173F13E4C5
n13:hasATCCode
n14:H05AA03
n3:absorption
The absolute bioavailability of 100 micrograms of Preotact after subcutaneous administration in the abdomen is 55%.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
68893-82-3
n3:clearance
PTH is rapidly cleared from plasma, primarily by Kupffer cells in the liver. To a lesser extent, PTH is cleared by filtration and reabsorption by the kidney.